Upregulated tumor sirtuin 2 expression correlates with reduced TNM stage and better overall survival in surgical breast cancer patients

  • Pengfei Shi
  • Min Zhou
  • Yonggang YangEmail author
Original Article



This study is aimed at exploring the correlation of sirtuin 2 (SIRT2) with clinical characteristics as well as overall survival (OS) in breast cancer patients.


Totally, 296 primary breast cancer patients who underwent surgical resection were retrospectively reviewed in this study, and SIRT2 expression in tumor and adjacent tissues was determined by immunohistochemistry (IHC) and scored by semiquantitative scoring (0–12). Clinicopathological features were retrieved, and OS was calculated.


Both SIRT2 IHC semiquantitative score and percentage of SIRT2 high expression by IHC score > 3 were lower in tumor tissues compared with adjacent tissues. Additionally, tumor SIRT2 high expression was associated with lower T stage, decreased N stage, and reduced TNM stage. Kaplan-Meier curves displayed that tumor SIRT2 high expression predicted longer OS. Univariate Cox’s regression analysis showed that tumor SIRT2 high expression was associated with prolonged OS, while multivariate Cox’s regression analysis displayed that tumor SIRT2 high expression was not an independent predictive factor for OS, which implied that tumor SIRT2 might predict OS indirectly through the interaction of tumor features (such as TNM stage) in breast cancer patients.


SIRT2 expression is lower in tumor tissues compared with adjacent tissues, and tumor SIRT2 high expression correlates with lower T stage, decreased N stage, reduced TNM stage, and longer OS in breast cancer patients.


Breast cancer Overall survival Predictive factor Sirtuin 2 TNM stage 


Compliance with ethical standards

The Ethical Committee of our hospital approved the protocol of this study. All enrolled patients or their guardians provided written informed consents or verbal agreements with recording.

Competing interests

The authors declare that they have no competing interests.


  1. 1.
    Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomark Prev 25(1):16–27. CrossRefGoogle Scholar
  2. 2.
    Harbeck N, Gnant M (2017) Breast cancer. Lancet 389(10074):1134–1150. CrossRefGoogle Scholar
  3. 3.
    Scully OJ, Bay BH, Yip G, Yu Y (2012) Breast cancer metastasis. Cancer Genomics Proteomics 9(5):311–320Google Scholar
  4. 4.
    Min JS, Kim JC, Kim JA, Kang I, Ahn JK (2018) SIRT2 reduces actin polymerization and cell migration through deacetylation and degradation of HSP90. Biochim Biophys Acta, Mol Cell Res 1865(9):1230–1238. CrossRefGoogle Scholar
  5. 5.
    Frye RA (2000) Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 273(2):793–798. CrossRefGoogle Scholar
  6. 6.
    Verdin E (2015) NAD(+) in aging, metabolism, and neurodegeneration. Science 350(6265):1208–1213. CrossRefGoogle Scholar
  7. 7.
    Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, Watanabe T, Ohama E, Tahimic CGT, Kurimasa A, Oshimura M (2003) Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 309(3):558–566CrossRefGoogle Scholar
  8. 8.
    Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, Mumm JS, Melnick AM, Bhalla KN (2016) SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress-inducing agents. Cancer Res 76(18):5467–5478. CrossRefGoogle Scholar
  9. 9.
    Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, Cha YI, Gius D, Deng CX (2011) SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20(4):487–499. CrossRefGoogle Scholar
  10. 10.
    Xu W, Jiang K, Shen M, Qian Y, Peng Y (2015) SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A. Biol Chem 396(8):929–936. CrossRefGoogle Scholar
  11. 11.
    Lai CC, Lin PM, Lin SF, Hsu CH, Lin HC, Hu ML, Hsu CM, Yang MY (2013) Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol 34(3):1847–1854. CrossRefGoogle Scholar
  12. 12.
    Du Y, Wu J, Zhang H et al (2017) Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression. Mol Med Rep 15(4):1638–1646. CrossRefGoogle Scholar
  13. 13.
    Li Y, Dai D, Lu Q et al (2013) Sirt2 suppresses glioma cell growth through targeting NF-kappaB-miR-21 axis. Biochem Biophys Res Commun 441(3):661–667. CrossRefGoogle Scholar
  14. 14.
    Damodaran S, Damaschke N, Gawdzik J, Yang B, Shi C, Allen GO, Huang W, Denu J, Jarrard D (2017) Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes. BMC Cancer 17(1):874. CrossRefGoogle Scholar
  15. 15.
    Ye SL, Li XY, Zhao K, Feng T (2017) High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma: a cohort study. Medicine (Baltimore) 96(15):e6472. CrossRefGoogle Scholar
  16. 16.
    Arora A, Dey CS (2014) SIRT2 negatively regulates insulin resistance in C2C12 skeletal muscle cells. Biochim Biophys Acta 1842(9):1372–1378. CrossRefGoogle Scholar
  17. 17.
    Suematsu T, Li Y, Kojima H, Nakajima K, Oshimura M, Inoue T (2014) Deacetylation of the mitotic checkpoint protein BubR1 at lysine 250 by SIRT2 and subsequent effects on BubR1 degradation during the prometaphase/anaphase transition. Biochem Biophys Res Commun 453(3):588–594. CrossRefGoogle Scholar
  18. 18.
    Gal J, Bang Y, Choi HJ (2012) SIRT2 interferes with autophagy-mediated degradation of protein aggregates in neuronal cells under proteasome inhibition. Neurochem Int 61(7):992–1000. CrossRefGoogle Scholar
  19. 19.
    Nguyen P, Lee S, Lorang-Leins D, Trepel J, Smart DK (2014) SIRT2 interacts with beta-catenin to inhibit Wnt signaling output in response to radiation-induced stress. Mol Cancer Res 12(9):1244–1253. CrossRefGoogle Scholar
  20. 20.
    Temel M, Koc MN, Ulutas S et al (2016) The expression levels of the sirtuins in patients with BCC. Tumour Biol 37(5):6429–6435. CrossRefGoogle Scholar
  21. 21.
    McGlynn LM, Zino S, MacDonald AI et al (2014) SIRT2: tumour suppressor or tumour promoter in operable breast cancer? Eur J Cancer 50(2):290–301. CrossRefGoogle Scholar
  22. 22.
    Li Z, Huang J, Yuan H, Chen Z, Luo Q, Lu S (2016) SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation. Oncotarget 7(14):18927–18939. Google Scholar
  23. 23.
    Gong J, Wang H, Lou W, Wang G, Tao H, Wen H, Liu Y, Xie Q (2018) Associations of sirtuins with clinicopathological parameters and prognosis in non-small cell lung cancer. Cancer Manag Res 10:3341–3356. CrossRefGoogle Scholar
  24. 24.
    Van Damme M, Crompot E, Meuleman N et al (2012) HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 7(12):1403–1412. CrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2019

Authors and Affiliations

  1. 1.Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Out-patient, The Central Hospital of Wuhan, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations